ProKidney Corp. filed a Current Report on Form 8-K on October 29, 2026, disclosing that it entered into an Open Market Sale Agreement with Jefferies LLC that would allow the company to sell up to $200,000,000 of Class A common stock in at-the-market offerings, subject to the effectiveness of a concurrently filed shelf registration statement.

Key Highlights

  • Agreement date: ProKidney Corp. entered into the Open Market Sale Agreement with Jefferies LLC on October 29, 2026.
  • Maximum offering size: The company may offer and sell Shares of up to a maximum aggregate offering price of $200,000,000 under the Sales Agreement, once the Registration Statement is effective.
  • Agent compensation: Jefferies LLC will be entitled to compensation of up to 3.0% of the gross offering proceeds of all Shares sold through it under the Sales Agreement.
  • Registration contingency: The issuance and sale of Shares is subject to the effectiveness of a shelf registration statement on Form S-3, filed with the SEC on October 29, 2026.
  • No obligation to sell: According to the filing, "The Company has no obligation to sell any of the Shares under the Sales Agreement and may at any time and from time to time suspend the offering of the Shares under the Sales Agreement."
  • Legal counsel: Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. provided the legal opinion relating to the validity of the Shares.

ProKidney Establishes At-the-Market Equity Facility with Jefferies LLC

ProKidney Corp. (NASDAQ:PROK), a Delaware-incorporated company headquartered in Winston-Salem, North Carolina, disclosed on October 29, 2026, that it entered into an Open Market Sale Agreement with Jefferies LLC, under which Jefferies will act as sales agent for potential sales of Class A common stock, par value $0.0001 per share. The filing was signed by Todd Girolamo, Chief Legal Officer, on behalf of the registrant.

According to the filing, sales under the agreement may be made "by any method permitted that is deemed to be an 'at the market' offering as defined in Rule 415(a)(4) under the Securities Act of 1933," and may occur in ordinary brokers' transactions, through a market maker, on The Nasdaq Capital Market or any other eligible market venue, in the over-the-counter market, in privately negotiated transactions, or through a combination of such methods. Jefferies LLC will receive compensation of up to 3.0% of gross offering proceeds, and the company also agreed to reimburse the Sales Agent for certain specified expenses.

The filing notes that the company makes no assurances as to whether the Registration Statement will become effective or, if effective, as to its continued effectiveness. The Sales Agreement contains customary representations, warranties, and covenants, and the company agreed to provide indemnification and contribution to Jefferies against certain liabilities, including under the Securities Act and the Securities Exchange Act of 1934. The filing also notes that Jefferies has previously provided, and in the future may provide, financial advisory and investment banking services to the company for customary fees.

What Was Disclosed

ProKidney Corp. disclosed the execution of an at-the-market equity offering agreement with Jefferies LLC, permitting sales of Class A common stock of up to $200,000,000 in aggregate, contingent on the effectiveness of a Form S-3 shelf registration statement filed the same day.